Sermorelin

Sermorelin binds to the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary gland, stimulating the synthesis and pulsatile release of endogenous growth hormone. This mechanism preserves the normal physiological feedback loop: when GH and IGF-1 levels rise, somatostatin release increases to modulate further GH secretion, preventing supraphysiological GH exposure. This contrasts with exogenous GH injection, which bypasses pituitary regulation. Sermorelin maintains the diurnal pattern of GH release, with the largest pulses occurring during slow-wave sleep. The 29-amino-acid fragment retains full biological activity at the GHRH receptor, as the N-terminal portion of GHRH contains the receptor-binding domain.

Vittone et al. (1997) demonstrated that sermorelin increased GH secretion and IGF-1 levels in GH-deficient and elderly adults, with improvements in body composition including reduced adiposity. The compound received FDA approval for pediatric GH deficiency based on clinical trial data showing improved growth velocity. As Geref, it was also approved for diagnostic assessment of pituitary GH reserve. Multiple smaller studies and clinical experience support its use for age-related GH decline, showing improvements in sleep quality, body composition, and skin quality, though large-scale RCTs in the adult anti-aging population are lacking. The evidence base is moderate (grade B) largely due to its prior FDA approval and established pharmacology, though current off-label adult use relies on smaller studies.

Sermorelin acetate (Geref) was FDA-approved for diagnostic and therapeutic use but the product was voluntarily withdrawn from the commercial market by the manufacturer. This withdrawal was for business and manufacturing reasons, not due to safety concerns. Sermorelin remains available through 503A and 503B compounding pharmacies in the United States and is one of the more commonly compounded peptides for anti-aging medicine. It is also available through grey-market peptide suppliers. WADA prohibits sermorelin in sport under the GH-releasing factors category.

IGF-1 levels should be measured at baseline and periodically (every 3 to 6 months) to assess GH axis response. GH stimulation testing can confirm pituitary responsiveness. Monitor body composition, sleep quality, and subjective well-being as clinical endpoints. Fasting glucose and HbA1c should be monitored, though sermorelin is less likely to impair glucose tolerance than exogenous GH. Assess for development of anti-drug antibodies if clinical response wanes over time.

These are general considerations for clinical awareness and do not constitute prescriptive monitoring recommendations for any individual patient.

Sermorelin is supplied as a lyophilized powder, typically at concentrations of 3 mg, 6 mg, or 9 mg per vial. Reconstitution with bacteriostatic water is standard. Reconstituted sermorelin should be refrigerated (2 to 8 degrees C) and used within 2 to 4 weeks. The peptide is susceptible to degradation if exposed to heat, light, or repeated freeze-thaw cycles. Administer subcutaneously, typically at bedtime to align with the physiological GH surge during sleep.

1. 1

   RCT

   Sermorelin (GHRH 1-29 NH2) Stimulation of Growth Hormone Secretion in GH-Deficient Adults

   Vittone J, Blackman MR, Busby-Whitehead J, et al. (1997). Journal of Clinical Endocrinology & Metabolism

   Key findings: Sermorelin increased GH secretion and IGF-1 levels in GH-deficient and elderly adults with age-related GH decline. Improved body composition measures including reduced adiposity.

   Limitations: Small sample size. Short treatment duration. Pre-approval study methodology.

2. 2

   FDA label

   Geref (sermorelin acetate for injection) Prescribing Information

   EMD Serono (1997). FDA

   Key findings: FDA-approved for diagnostic evaluation of pituitary GH secretion and for treatment of idiopathic GH deficiency in children with growth failure. Dosing, safety, and contraindication data included.

   Limitations: Product voluntarily withdrawn from commercial market (not for safety reasons). Label reflects pediatric indication primarily.

3. 3

   review

   GHRH Analogues: Current Status and Future Perspectives in Growth Hormone Therapy

   Sigalos JT, Pastuszak AW. (2018). Sexual Medicine Reviews

   Key findings: Review of GHRH analogues including sermorelin, tesamorelin, and CJC-1295. Discusses the clinical rationale for GHRH-based GH stimulation as a more physiological approach than exogenous GH administration.

   Limitations: Review article. Limited discussion of long-term safety data for sermorelin.